H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...

BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced interim ...

Soquelitinib reduced EASI scores by 55.9% at 28 days and 69.1% at 58 days versus 27.0% and 19.1% for placebo. At day 58, 90% of soquelitinib patients achieved EASI 50, with no significant safety ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

After hours: January 3 at 7:43:18 p.m. EST ...

"A lot of research on bird intelligence has focused on various species of crows, particularly the New Caledonian crow (Corvus moneduloides), which is renown for its tool-making ability.

Today, a brief rundown of news involving Tessera Therapeutics and Corvus Pharmaceuticals, as well as updates from Sarepta Therapeutics, Cara Therapeutics and Johnson & Johnson that you may have missed ...